Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jacqueline A. Pesa, Dilesh Doshi, Li Wang, Huseyin Yuce & Onur Baser. (2017) Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Current Medical Research and Opinion 33:4, pages 723-731.
Read now
Read now
Fan Zhang, Tianmei Si, Chiun-Fang Chiou, Anthony WF Harris, Chang Yoon Kim, Padmashree Jahagirdar & Steve Ascher. (2015) Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 11, pages 657-668.
Read now
Read now
Onur Baser, Lin Xie, Jacqueline Pesa & Mike Durkin. (2015) Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. Journal of Medical Economics 18:5, pages 357-365.
Read now
Read now
Marie-Hélène Lafeuille, Jason Dean, Valerie Carter, Mei Sheng Duh, John Fastenau, Riad Dirani & Patrick Lefebvre. (2014) Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Current Medical Research and Opinion 30:8, pages 1643-1655.
Read now
Read now
Larry Alphs, Cynthia A Bossie, Dong-Jing Fu, Yi-Wen Ma & Jennifer Kern Sliwa. (2014) Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. Expert Opinion on Pharmacotherapy 15:7, pages 1029-1042.
Read now
Read now
Jennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, Ibrahim Turkoz & Larry Alphs. (2012) Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment 8, pages 375-385.
Read now
Read now
Mahesh N Samtani, John J Sheehan, Dong-Jing Fu, Bart Remmerie, Jennifer Kern Sliwa & Larry Alphs. (2012) Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. Clinical Pharmacology: Advances and Applications 4, pages 25-40.
Read now
Read now
Pierre Chue & James Chue. (2012) A review of paliperidone palmitate. Expert Review of Neurotherapeutics 12:12, pages 1383-1397.
Read now
Read now
Articles from other publishers (23)
Hwanhee Hong, Lu Liu, Ramin Mojtabai & Elizabeth A. Stuart. (2023) Calibrated meta-analysis to estimate the efficacy of mental health treatments in target populations: an application to paliperidone trials for treatment of schizophrenia. BMC Medical Research Methodology 23:1.
Crossref
Crossref
Giouliana Kadra-Scalzo, Deborah Ahn, Alex Bird, Matthew Broadbent, Chin-Kuo Chang, Megan Pritchard, Hitesh Shetty, David Taylor, Richard Hayes & Robert Stewart. (2022) Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses. BMJ Open 12:4, pages e051567.
Crossref
Crossref
Massimo Carlo Mauri, Gemma Franco, Alessandro Minutillo, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Sara Baldelli & Dario Cattaneo. (2022) The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly. Journal of Clinical Psychopharmacology 42:1, pages 23-30.
Crossref
Crossref
Anna Ceraso, Jessie Jingxia LIN, Johannes Schneider-Thoma, Spyridon Siafis, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis & Stefan Leucht. (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Crossref
Dasom Lee, Boung Chul Lee, Soo-Hee Choi, Do-Hyung Kang, Duk-In Jon & Myung Hun Jung. (2020) Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea. Clinical Psychopharmacology and Neuroscience 18:2, pages 303-310.
Crossref
Crossref
José Miguel Meca García, Miguel Soto Ontoso, Eliana Gómez Padrón, María Rosa Sanchez-Waisen Hernández & Yaiza Rojas Vallejo. (2020) Estudio observacional sobre los efectos del palmitato de paliperidona inyectable mensual sobre la hospitalización y asistencia urgente. Psiquiatría Biológica 27:2, pages 43-46.
Crossref
Crossref
R. Patel, E. Chesney, M. Taylor, D. Taylor & P. McGuire. (2017) Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?. Psychological Medicine 48:10, pages 1616-1623.
Crossref
Crossref
Anna-Marie Mortlock, Fintan Larkin, Callum C. Ross, Nitin Gupta, Samrat Sengupta & Mrigendra Das. (2017) Effectiveness of paliperidone depot injection in seriously violent men with comorbid schizophrenia and dissocial personality disorder in a UK high-security hospital. Therapeutic Advances in Psychopharmacology 7:5, pages 169-179.
Crossref
Crossref
A. Carlo Altamura, Giuseppe Delvecchio, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Alessio Fiorentini, M. Donatella Mirabile, Riccardo A. Paoli, Claudia Cinnante, Fabio Triulzi, Massimo C. Mauri & Paolo Brambilla. (2017) Gray matter volumes may predict the clinical response to paliperidone palmitate long-acting in acute psychosis: A pilot longitudinal neuroimaging study. Psychiatry Research: Neuroimaging 261, pages 80-84.
Crossref
Crossref
Jesús E. Mesones-Peral, Pedro Gurillo-Muñoz, Mari Paz Sánchez-Sicilia, Adam Miller & Alejandra Griñant-Fernández. (2017) Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection. Revista de Psiquiatría y Salud Mental (English Edition) 10:1, pages 33-37.
Crossref
Crossref
Jesús E. Mesones-Peral, Pedro Gurillo-Muñoz, Mari Paz Sánchez-Sicilia, Adam Miller & Alejandra Griñant-Fernández. (2017) Hospitalizaciones y análisis económico en pacientes psicóticos con palmitato de paliperidona de larga duración. Revista de Psiquiatría y Salud Mental 10:1, pages 33-37.
Crossref
Crossref
D.M. Taylor, A. Sparshatt, M. O’Hagan & O. Dzahini. (2020) Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort – a four-year mirror image study. European Psychiatry 37, pages 43-48.
Crossref
Crossref
Javier Quintero, Itziar Oyagüez, Beatriz González, Ignacio Cuervo-Arango, Ignacio García & Miguel Angel Casado. (2016) Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. Clinical Drug Investigation 36:6, pages 479-490.
Crossref
Crossref
Jacqueline A. Pesa, Erik Muser, Leslie B. Montejano, David M. Smith & Oren I. Meyers. (2015) Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics. Drugs - Real World Outcomes 2:4, pages 377-385.
Crossref
Crossref
Yongling Xiao, Erik Muser, Marie-Hélène Lafeuille, Jacqueline Pesa, John Fastenau, Mei Sheng Duh & Patrick Lefebvre. (2015) Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. Journal of Comparative Effectiveness Research 4:6, pages 579-592.
Crossref
Crossref
Marie-Hélène Lafeuille, Amanda Melina Grittner, Jonathan Fortier, Erik Muser, John Fasteneau, Mei Sheng Duh & Patrick Lefebvre. (2015) Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. American Journal of Health-System Pharmacy 72:5, pages 378-389.
Crossref
Crossref
Marie-Hélène Lafeuille, François Laliberté-Auger, Patrick Lefebvre, Christian Frois, John Fastenau & Mei Sheng Duh. (2013) Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 13:1.
Crossref
Crossref
Rahul ManchandaPierre ChueAshok MallaPhil TibboMarc-André RoyRichard WilliamsSrividya IyerDanyael LutgensNicola Banks. (2017) Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use. The Canadian Journal of Psychiatry 58:5_suppl, pages 5-13.
Crossref
Crossref
Fiore Lalla & Larry Arshoff. (2013) A Mental Health Initiative to Enhance Schizophrenia Treatment Efficacy. Healthcare Management Forum 26:1, pages 46-50.
Crossref
Crossref
David Koczerginski & Lorna Thompson. (2012) Déterminer les tendances et les transitions dans la prise en charge de patients atteints de schizophrénie aux consultations externes des hôpitaux. Healthcare Management Forum 25:3_suppl, pages S65-S70.
Crossref
Crossref
David Koczerginski & Lorna Thompson. (2012) Identifying Trends and Transitions in the Hospital Outpatient Management of Patients with Schizophrenia. Healthcare Management Forum 25:3_suppl, pages S59-S64.
Crossref
Crossref
Abraham M Nussbaum & T S Stroup. (2012) Paliperidone palmitate for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Natalie J. Carter. (2012) Extended-Release Intramuscular Paliperidone Palmitate. Drugs 72:8, pages 1137-1160.
Crossref
Crossref